San Antonio Breast Cancer Symposium
The company has faced some early hurdles in joining competitors in the colorectal cancer space but believes it can claim first mover status in early breast cancer.
Investigators presented data from a meta-analysis that suggests the firm's POLAR gene expression test can identify patients unlikely to benefit from radiation.
Biocept to Refocus CNSide Assay Plans After FDA Feedback Suggests Targeting Narrower Indications
Premium
The company failed in its first bid for breakthrough device designation but has now split out new specific indications for which it is building more persuasive utility data.
Foundation Medicine's ctDNA assay was able to subclassify patients into higher and lower recurrence risk groups with CTCs providing an additional boost.